Essential Drugs List for Uganda (EDLU) 2001

The National Drug Authority

© 2001 by The National Drug Authority

All parts of this publication may be reproduced in any form, provided due acknowledgement is given.

Copies may be obtained from:

The Executive Secretary/Registrar
National Drug Authority
PO Box 23096, Kampala
Uganda
Tel: 255665 / 255628 / 347391/2
Fax: 255758
Email: nda@imul.com

Computer typeset in Arial TrueType

Printed and bound in Uganda by
Marianum Press, PO Box 11, Kisubi

ISBN 9970-719-00-9

Foreword

It is my pleasure to present this revised and updated Essential Drugs List for Uganda (EDLU) 2001 to all prescribing and dispensing staff, and to other health professionals handling medicines in Uganda.

This 3rd edition of EDLU has been produced in order to take account of the various changes which have taken place in therapeutic practice over the 5 year period since the last edition.

Essential drugs are those which satisfy the needs of the majority of the population and should therefore always be available in adequate amounts and appropriate dose forms. EDLU lists those essential drugs considered to be the most appropriate for use in the Uganda public health system. It is also strongly recommended as a rational basis for private sector prescribing.

In order to ensure that the correct decision is taken on whether to include a particular item or not, consideration must be made of a number of key criteria including:

- **Efficacy**: the capacity of the medicine effectively to treat the diagnosed condition
- **Safety**: the therapeutic index of the drug (ratio of treatment dose to toxic dose) and
the nature, frequency and severity of expected side-effects

➢ **Quality**: compliance of the drug presentation with internationally accepted standards of purity, composition, and consistency

➢ **Cost-effectiveness**: considered in terms of available and effective alternative medicines or dose-forms

➢ **Appropriateness**: the overall suitability of the medicine within the local context taking account of various factors including:

  • Changing morbidity patterns
  • Stability in storage
  • Likely compliance with dose regime
  • Development of resistance
  • Type of dose form/method of administration
  • Socio-economic factors

In preparing the new EDLU, these criteria have been carefully considered by the Committee on Essential Drugs (CED), assisted as required by experts in the various medical specialities.

Drug lists by their very nature are subject to rapid obsolescence due to ever-changing therapeutic requirements for the treatment of conditions found in Uganda. A good example of this is the treatment of malaria which has had to be revised recently to take account of rapidly developing resistance to previous first-line medication.

Thus the list should be subject to constant scrutiny and updated accordingly. This process is highly dependent on the input of clinicians in the field who should therefore continuously assess the appropriateness of the selected medicines for treating the conditions encountered. Clinicians are encouraged to submit proposals for amendments to EDLU following the procedures given in the Preface.

The EDLU is a guide for drug selection and level of distribution and is meant to be used together with the National Standard Clinical Guidelines (NSCG) which give practical guidance on diagnosis and appropriate therapeutic approaches. Both publications are also useful resource materials for training in all aspects of rational drug use.

I wish to thank the Chairman and members of the National Drug Authority Committee on Essential Drugs for the time and effort they have put into the production of this excellent and vital document.

It is my sincere hope that routine use of the EDLU in combination with the NSCG by all levels of prescriber in their daily work will greatly assist in ensuring that patients receive optimum treatment of their health problems at all times.

However this will only be possible if adequate quantities of the recommended drugs are constantly available for utilisation at the appropriate level of health unit.

The Ministry of Health is therefore committed to improving accessibility to required essential drugs through active implementation of the new *National Drug Policy* which aims *inter alia* at securing adequate funding of essential drugs procurement and improved management of the drug supply system at all levels.
Preface and Acknowledgements

1. Background to EDLU 2001

The first and second editions of EDLU were produced in 1991 and 1996 respectively. As with these previous editions which it now supersedes, this new EDLU 2001 is produced with the aim of assisting in making accessible and affordable to the majority of the population those drugs which are necessary for the prevention and treatment of common health problems in the country.

The EDLU lists those essential drugs considered to be most suitable for current use in Uganda. The current WHO model list (11th revision December 1999) was used as a basis for EDLU and modified to suit the requirements of Uganda according to the criteria given in the Foreword by the Honourable Minister of Health, and taking into account available resources and currently applicable clinical practice.

According to the National Drug Policy the EDLU is a ‘primary drug management tool at all levels of the health system’ and is intended to ‘to strengthen and harmonise the essential drugs selection process at national and district levels for both public and private sectors’. The EDLU should be used ‘as a basis for procurement, prescribing and dispensing in the public health system and its use promoted in the private (profit and non-profit) sector’.

Thus it is important to stress that, although the list is designed primarily for public sector use, it is equally appropriate for private sector prescribers who are strongly encouraged to select EDLU drugs whenever possible. Numerous changes have been made to EDLU to bring it into line with currently accepted therapeutic requirements. These are summarised on pages xix-xxvi.

2. Amendment of EDLU 2001

As stated in the Foreword, the EDLU will be subject to constant review and revision. All clinicians should therefore fully familiarise themselves with the contents of the EDLU and continuously evaluate its relevance and appropriateness to their daily work.

Proposals for amendments to EDLU, together with supporting arguments and any available relevant literature, should be forwarded in writing to:

The Chairman
National Drug Authority Committee on Essential Drugs
PO Box 23096, Kampala
Tel: 255665 / 255628 / 347391 / 347392
Fax: 255758
Email nda@imul.com

According to the National Drug Policy, the EDLU is supposed to be revised at least every three years, thus the next edition should be produced by 2004.

In the meantime, any proposals will be discussed by the Committee on Essential Drugs. Agreed amendments to the list will be notified to all prescribers through Ministry of Health circulars as appropriate.

3. Acknowledgements
Preparation of this vital publication would not have been possible without the dedication and hard work of my fellow contributing members of the Committee on Essential Drugs who are listed on pages xv-xvi and without the invaluable contributions of the key clinical specialists listed on page xvii. I wish to express my sincere thanks to them all for their time and efforts.

I am also greatly indebted to the Chairman and Executive Secretary / Registrar of NDA for facilitating the completion of this work through the provision of a most suitable and supportive working environment and to the NDA Secretariat staff for their continuous technical and administrative support.

Dr A Lukanga-Ndawula  
MB ChB, FRCS(Ed)  
Chairman, NDA Committee on Essential Drugs

Contributing Members of the NDA Committee on Essential Drugs (CED)

1. Dr A Lukanga-Ndawula  
   *Chief of Medical Services, Uganda Peoples Defence Forces (UPDF)*  
   *Chairman, Committee on Essential Drugs*

2. Dr E Owino  
   *Head, Dept. of Pharmacy, Makerere University*

3. Dr G W Zirembuzi  
   *Senior Consultant Paediatrician, Mulago Hospital, Kampala*

4. Dr J G M Jagwe (ex officio)  
   *Chairman, NDA*

5. Prof G R Nzarubara  
   *Surgeon, Dept. of Surgery, Mulago Hospital, Kampala*

6. Dr C W Kadama  
   *Private Medical Practitioner, Centenary Clinic, Kampala representing the Private Medical Practitioners Association*

7. Ms D A Kusemererwa  
   *Senior Pharmacist, Joint Medical Store (JMS), Kampala*

8. Dr E K Kanyesigye  
   *Assistant Commissioner of Health Services (Clinical)*  
   *Ministry of Health, Kampala*
9. Mr G K Sematiko

Senior Pharmacist, Mulago Hospital, Kampala

10. Dr B A Mpeka-Tusubira

Assistant Commissioner Clinical Services
Ministry of Health, Kampala

11. Dr S Ndyanabangi

Principal Medical Officer, Ministry of Health, Kampala

12. Mrs C Ntegyeka

Pharmacist, Dept. of Pharmacy, Makerere University

13. Dr J C Lule

Acting Executive Secretary / Registrar
National Drug Authority
Secretary, Committee on Essential Drugs

14. Mr C J Forshaw

Pharmaceutical Advisor, National Drug Authority
DANIDA/Uganda Health Sector Support Programme
Editor, EDLU

Contributing Clinical Specialists

1. Dr M Mungherera

Psychiatrist,
Butabika Hospital, Kampala

2. Prof T Clshoz

Professor of Anaesthesiology,
University Hospital, Mbarara

3. Associate Prof M Kawuma

Dept. of Ophthalmology,
Makerere Medical School, Mulago Hospital, Kampala

4. Dr J V B Tindimwebwa

Head, Dept. of Anaesthesia,
Makerere Medical School, Mulago Hospital, Kampala

5. Mr E K Naddumba
Presentation of Information

1. General

**Drug names:** the relevant International Non-proprietary Name (INN) or generic name are used throughout the list. According to the National Drug Policy and Authority Statute 1993 sec 12 generic names shall be used for prescribing and labelling (ie. including dispensing) of drugs, except where no such generic or suitable alternative non-proprietary name exists.

**Order of sections:** drugs are arranged in alphabetical order by pharmacological / therapeutic groups following the same basic arrangement as the WHO Model List of Essential Drugs with the addition of two additional sections: 28: Ear, Nose and Oropharyngeal Preparations and 29: Drugs for Neurosurgical Use.

2. Level of Use

For each item the lowest level of health care facility at which the item may be used is indicated as shown in the table below. This designation is in line with the diagnostic and clinical skills expected to be available at that level. In certain cases the use of an item is further restricted to facilities where a specific type of clinical and/or diagnostic expertise is available, eg. certain ophthalmological preparations. The in-charge of each level of Health Centre is given in parentheses.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HC1</td>
<td>Health Centre 1 (Community Level)</td>
</tr>
<tr>
<td>HC2</td>
<td>Health Centre 2 (Enrolled Comprehensive Nurse)</td>
</tr>
<tr>
<td>HC3</td>
<td>Health Centre 3 (Clinical Officer)</td>
</tr>
<tr>
<td>HC4</td>
<td>Health Centre 4 (Medical Officer)</td>
</tr>
<tr>
<td>H</td>
<td>Hospital</td>
</tr>
<tr>
<td>R</td>
<td>Restricted Use (ie. needs high level diagnostic/clinical skills only available in specialised institutions, eg. Cancer Institute, National Psychiatric Hospital, etc.)</td>
</tr>
<tr>
<td>Ref</td>
<td>Referral Hospital</td>
</tr>
</tbody>
</table>

Notes:

1. **Diagnostic facilities:** Health facilities of levels HC3 and higher have different degrees of laboratory diagnostic support facilities available.

2. **Drug availability:** all of the items listed for health centre levels up to and including H (Hospital) level are expected to be available at all times from National Medical Stores. More specialised items with an R (Restricted) or Ref (Referral) designation will be available from NMS only at the request of the relevant institution. It is therefore important that accurate estimates for the annual requirements for these items are made by the institutions concerned well in advance and the information forwarded to NMS so that sufficient quantities of the required items may be procured and held in stock.

**Abbreviations and Units**

- **BNF** = British National Formulary
- **BP** = British Pharmacopoeia
**Summary of Main Changes in EDLU 2001**

**A. Additions**

**1.1 General anaesthetics and oxygen**
- propofol injection 10mg/mL IV R

**1.2 Local anaesthetics**
- lignocaine spray 10% HC4

**1.3 Preoperative and peri-operative medication**
- ephedrine hydrochloride injection 3mg/mL Ref
- fentanyl injection 50µg/mL Ref
- midazolam injection 2mg/mL Ref

**2.3 Opioid analgesics**
- morphine oral solution 1mg/mL HC3

**4.1 Antidotes (General)**
- charcoal activated tablet 250mg HC2

**4.2 Antidotes (Specific)**
- sodium thiosulphate injection 250mg or 500mg/mL H

**6.1.1 Intestinal anthelminthics**
- mebendazole tablet 500mg HC1

**6.2.1 Penicillins**
- flucloxacillin oral susp (PFR) 125mg/5mL HC4

**6.2.2 Other antibacterial drugs**
- ceftriaxone powder for inj 250mg IV/IM Ref
- ciprofloxacin tablet 500mg HC3

**6.2.4 Antituberculosis drugs**
ethambutol + isoniazid tablet 400mg + 150mg HC4

6.3 Antifungal drugs
clotrimazole pessary 500mg HC4

6.4.1 Antiamoebic drugs
tinidazole tablet 500mg HC4

6.4.3 Antimalarial drugs
artemether injection 100mg IM HC4
artemether tablet 50mg HC4
sodium artesunate tablet 50mg HC4

6.4.4 Antitrypanosomal drugs (African trypanosomiasis)
nifurtimox tablet 30mg R
nifurtimox tablet 120mg R
nifurtimox tablet 250mg R

6.4.6 Drugs used in toxoplasmosis
clindamycin capsule 150mg HC4
pyrimethamine tablet 25mg HC4

10.1 Antинаemia drugs
ferrous sulphate + folic acid tab 60mg elem.iron + 400µg HC1

12.1 Antianginal drugs
atenolol tablet 100mg H

12.2 Antidysrhythmic drugs
atenolol tablet 100mg H

12.3 Antihypertensive drugs
nifedipine tablet 10mg H
nifedipine tablet 20mg SR H

12.4.2 Drugs used in vascular shock
hydrocortisone sod. succinate injection (PFR) 100mg IV/IM HC3

13.1 Topical antifungals
miconazole cream 2% H

13.2 Topical antiinfectives
potassium permanganate solution aq 1:10,000 (0.01%) HC4
silver sulphadiazine cream 1% HC3

13.3 Topical antiinflammatories and antipruritics
betamethasone cream or ointment 0.1% HC4

13.4 Keratoplastics and keratolytics
benzoyl peroxide lotion or cream 5% HC4

13.6 Pediculicide
malathion lotion or cream 5% HC2

14.1 Ophthalmic diagnostic agents
rose bengal eye drops 1% HC4

17.1 Antacids and other antiulcer drugs
omeprazole tablet 20mg H

17.2 Antiemetics
cyclizine tablet 50mg Ref
cyclizine inj 50mg/mL IM/slow IV Ref
domperidone tablet 10mg H
domperidone suspension 5mg/5mL H
domperidone suppository 30mg H
17.4 Antispasmodics
propantheline tablet 15mg H
17.6 Laxatives
senna tablet 7.5mg HC2
17.7.2 Antidiarrhoeals
loperamide tablet or capsule 2mg H
18.1 Adrenal hormones & synthetic substitutes
dexamethasone tablet 4mg H
18.5 Insulins and other antidiabetic agents
isophane insulin injection 100 IU/mL SC HC4
19.1 Diagnostic agents
tuberculin PPD injection 100 IU/mL HC3
19.2 Sera and immunoglobulins
antirabies immunoglobulin, human IM/local infiltration HC4
20. Muscle relaxants & cholinesterase inhibitors
atracurium besylate injection 10mg/mL Ref
21.1.1 Antiinfective + antiinflammatory agents
neomycin + betamethasone eye drops 0.5% + 0.1% HC4
22.1 Oxytocics
ergometrine + oxytocin injection 500µg + 5 IU/mL IM HC2
22.2 Antioxytocics
salbutamol injection 1mg/mL IV inf HC4
25.1 Antiasthmatic drugs
aminophylline tablet 100 mg HC3
cromoglycic acid inhaler 5mg/metered dose (for adults) HC4
salbutamol nebuliser solution 2.5mg/mL H
salbutamol nebuliser solution 5mg/mL H
25.2 Antitussive drug
codeine phosphate tablet 30mg HC4
27. Vitamins and minerals
ergocalciferol tablet or capsule 250µg Ref
pyridoxine tablet 50mg HC4
retinol (vitamin A) capsule (drops) 50,000 IU HC2
retinol (vitamin A) capsule (drops) 100,000 IU HC2
28.1 Ear preparations
betamethasone ear/eye drops 0.1% H
28.3 Oropharyngeal preparations
povidone-iodine mouthwash/gargle 1% HC3
triamcinolone acetonide oral paste 0.1% H
B. Deletions

1.2 Local anaesthetics
lignocaine spray 5% Hosp

2.1 Non-opioids
acetylsalicylic acid tablet 75mg HC

3. Anti-allergics & drugs used in anaphylaxis
astemizole tablet 10mg Ref

4.1 Antidotes (General)
charcoal activated tablet 50mg HC

4.2 Antidotes (Specific)
ferric hexacyanoferrate powder Hosp
sodium thiosulphate injection 1.5G/50mL Hosp

5. Antiepileptics and anticonvulsants
phenobarbitone (phenobarbital) tablet 30mg HC
phenobarbitone tablet 60mg HC

6.1.1 Intestinal anthelmintics
mebendazole tablet 100mg HC

6.1.3 Antischistosomals
niridazole tablet 600mg Ref

6.2.1 Penicillins
ampicillin powder for syrup 125mg/5mL Hosp
ampicillin tablet or capsule 250mg Hosp
cloxacillin powder for syrup 125mg/5mL Hosp

6.2.2 Other antibacterial drugs
cephalexin tablet 250mg R
lincomycin capsule 500mg Ref
tetracycline tablet / capsule 250mg HC

6.2.4 Antituberculosis drugs
rifampicin tablet / capsule 150mg Ref

6.4.3 Antimalarial drugs
chloroquine injection 200mg base/5mL HC
primaquine tablet 15mg HC
pyrimethamine tablet 25mg Hosp

8.3 Hormones and antihormones
stilboestrol tablet 5mg R

12.1 Antiangina drugs
cinnarizine tablet 75mg Ref
propranolol tablet 40mg Hosp

12.3 Antihypertensive drugs
diazoxide injection 300mg/20mL Hosp

13.1 Topical antifungals
griseofulvin tablet 250mg, 500mg Hosp

13.4 Astringent drugs
aluminium diacetate solution 13% Hosp
14.1 Ophthalmic diagnostic agents
homatropine eye drops 1% Hosp

17.2 Antiemetics
chlorpromazine tablet 25mg HC
chlorpromazine injection 25mg/mL deep IM Hosp
chlorpromazine suppository 100mg Hosp
prochlorperazine suppository 5mg HC
prochlorperazine suppository 25mg HC

17.4 Anti-inflammatory drug
sulfasalazine tablet 500mg R

17.5 Antispasmodic drugs
atropine injection 1mg/mL Hosp
hyoscine butylbromide tablet 10mg Hosp

18.1 Adrenal hormones and synthetic substitutes
vasopressin spray 10µg/dose Ref
vasopressin injection 5 IU Ref

18.7 Progestogens
medroxyprogesterone acetate injection 50mg/mL HC

19.1 Diagnostic agents
tuberculin, PPD with Tween 80 injection 5 IU/0.1mL HC
tuberculin, PPD with Tween 80 injection 5 IU/mL HC

19.2 Sera and immunoglobulins
antirabies immunoglobulin, injection 1,000 IU Hosp
human IM/local infiltration

19.3.2 Vaccines for specific groups of individuals
cholera vaccine inj 10mL/vial, 1.5mL/vial Hosp

21.1.1 Antiinfective + antiinflammatory agents
neomycin + beclomethasone eye drops 0.5% + 0.1% R

25.1 Antiasthmatic drugs
aminophylline tablet 200 mg HC

cromoglycic acid inhaler 1mg/dose Ref

25.2 Antitussive drug
codeine phosphate tablet 10mg Hosp

26.2 Parenterals

glucose infusion 10% HC

26.3 Miscellaneous

water for injection injection 100mL HC

27. Vitamins and minerals
calciferol injection 10,000 IU Hosp

pyridoxine tablet 25mg Hosp

vitamin B+C (Parenterovite) injection 5mL Ref

yeast dried tablet 300mg Hosp

28.1 Ear preparations
boric acid in spirit ear drops 1:16 (6.25%) H
ESSENTIAL DRUGS LIST FOR UGANDA

1. ANAESTHETICS

1.1 General anaesthetics and oxygen

1 Soda lime must be available for CO$_2$ absorption during closed circuit general anaesthesia

ether inhalation HC4
halothane inhalation HC4
ketamine injection 50mg/mL IV/IM HC4
ketamine injection paed 10mg/mL IV/IM HC4
nitrous oxide medical gas HC4
oxygen medical gas HC4
propofol injection 10mg/mL IV Ref
thiopental injection (PFR) 500mg IV HC4

1.2 Local anaesthetics

bupivacaine injection 0.25% IT/SC Ref
bupivacaine injection 0.5% IT/SC Ref
ethyl chloride spray HC3
lignocaine injection 2% (epidural) H
lignocaine dental cartridge 2% HC4
lignocaine injection 2% HC2
lignocaine spray 10% HC4
lignocaine paste 2-4% HC4
1.3 Preoperative and peri-operative medication

**2. ANALGESICS, ANTIPYRETICS**

### 2.1 Non-opioids

- acetylsalicylic acid tablet 300mg HC1
- diclofenac tablet 25mg HC4
- diclofenac injection 25mg/mL IV/IM H
- ibuprofen tablet 200mg HC2
- paracetamol tablet 500mg HC1
- paracetamol suppository 100mg HC3

### 2.2 Drugs used for gout

- allopurinol tablet 100mg HC4
- colchicine tablet 500µg HC4
- indomethacin tablet 25mg HC4
- probenecid tablet 500mg HC4

### 2.3 Opioid analgesics

- codeine tablet 30mg HC4
- dihydrocodeine tablet 30mg HC4
- morphine injection 15mg/mL IV/IM/SC HC4
- morphine oral solution 1mg/mL HC3
- morphine tablet 30mg HC4
- morphine tablet SR 10mg HC3
- morphine tablet SR 30mg HC3
- morphine tablet SR 60mg HC3
- papaveretum + hyoscine injection 15.4mg + 0.4mg Ref
- pethidine tablet 50mg HC4
3. ANTI-ALLERGICS & DRUGS USED IN ANAPHYLAXIS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength/Volume</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorphenamine</td>
<td>Tablet</td>
<td>4mg</td>
<td>HC2</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>Tablet</td>
<td>4mg</td>
<td>H</td>
</tr>
<tr>
<td>Cyproheptadine</td>
<td>Syrup</td>
<td>2mg/5mL</td>
<td>H</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Injection</td>
<td>4mg/mL IV/IM</td>
<td>HC4</td>
</tr>
<tr>
<td>Epinephrine (adrenaline)</td>
<td>Injection</td>
<td>1mg/mL IV/IM/SC</td>
<td>HC2</td>
</tr>
<tr>
<td>Hydrocortisone sod. succinate</td>
<td>Injection (PFR)</td>
<td>100mg IV/IM</td>
<td>HC3</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>Tablet</td>
<td>5mg</td>
<td>HC4</td>
</tr>
<tr>
<td>Promethazine</td>
<td>Tablet</td>
<td>25mg</td>
<td>HC2</td>
</tr>
<tr>
<td>Promethazine</td>
<td>Injection</td>
<td>25mg/mL slow IV/IM</td>
<td>HC4</td>
</tr>
</tbody>
</table>

4. ANTIDOTES

4.1 General

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength/Volume</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charcoal activated</td>
<td>Tablet</td>
<td>250mg</td>
<td>HC2</td>
</tr>
<tr>
<td>Ipecacuanha</td>
<td>Syrup</td>
<td>0.14%</td>
<td>HC2</td>
</tr>
<tr>
<td>Pralidoxime</td>
<td>Injection</td>
<td>200mg/mL IV/IM</td>
<td>HC4</td>
</tr>
</tbody>
</table>

4.2 Specific

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength/Volume</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atropine</td>
<td>Injection</td>
<td>1mg/mL IV/IM</td>
<td>HC4</td>
</tr>
<tr>
<td>Benztropine</td>
<td>Injection</td>
<td>1mg/mL IV/IM</td>
<td>HC4</td>
</tr>
<tr>
<td>Calcium folinate (folinic acid)</td>
<td>Tablet</td>
<td>15mg</td>
<td>Ref</td>
</tr>
<tr>
<td>Calcium folinate (folinic acid)</td>
<td>Injection</td>
<td>3mg/mL IV/IM</td>
<td>Ref</td>
</tr>
<tr>
<td>Deferoxamine</td>
<td>Injection (PFR)</td>
<td>500mg IV</td>
<td>H</td>
</tr>
<tr>
<td>Dimercaprol</td>
<td>Injection</td>
<td>50mg/mL IM</td>
<td>H</td>
</tr>
<tr>
<td>Methionine</td>
<td>Tablet</td>
<td>250mg</td>
<td>H</td>
</tr>
<tr>
<td>Methylthioninium chloride (methylene blue)</td>
<td>Injection</td>
<td>10mg/mL IV</td>
<td>H</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injection</td>
<td>400µg/mL IV/IM/SC</td>
<td>HC4</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injection (PFR)</td>
<td>20µg/mL IV/IM/SC</td>
<td>HC4</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>Tablet</td>
<td>250mg</td>
<td>H</td>
</tr>
<tr>
<td>Sodium calcium edetate</td>
<td>Injection</td>
<td>200mg/mL IV</td>
<td>H</td>
</tr>
<tr>
<td>Sodium nitrite</td>
<td>Injection</td>
<td>30mg/mL IV</td>
<td>H</td>
</tr>
<tr>
<td>Sodium thiosulphate</td>
<td>Injection</td>
<td>250mg or 500mg/mL IV</td>
<td>H</td>
</tr>
</tbody>
</table>

5. ANTIEPILEPTICS AND ANTICONVULSANTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength/Volume</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>Tablet</td>
<td>200mg</td>
<td>HC4</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Syrup</td>
<td>100mg/5mL</td>
<td>HC4</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>Tablet</td>
<td>2mg</td>
<td>Ref</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>Injection</td>
<td>500mg/mL IV</td>
<td>Ref</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Injection</td>
<td>5mg/mL IV</td>
<td>HC4</td>
</tr>
</tbody>
</table>
6. ANTI-INFECTIVE DRUGS

6.1 Anthelmintics

6.1.1 Intestinal anthelminthics

- mebendazole tablet 500mg HC1
- niclosamide tablet 500mg HC4

6.1.2 Antifilarials

- diethylcarbamazine tablet 50mg H
- ivermectin tablet 6mg HC3

6.1.3 Antischistosomals

- praziquantel tablet 600mg HC3

6.2 Antibacterials

6.2.1 Beta Lactam Drugs

- amoxicillin tablet or capsule 250mg HC2
- amoxicillin tablet or capsule 500mg HC2
- amoxicillin inj (PFR) 500mg IV/IM/IVinf HC4
- amoxicillin syrup (PFR) 125mg/5mL HC2
- amoxicillin + clavulanic acid tablet 250mg + 125mg Ref
- ampicillin inj (PFR) 500mg IV/IM/IVinf HC4
- benzathine benzylpenicillin injection (PFR) 2.4 MU IM HC3
- benzylpenicillin inj (PFR) 1MU (600mg) IM HC2
- ceftriaxone injection (PFR) 250mg IV/IM Ref
- cefuroxime axitel tablet 250mg Ref
- cefuroxime sodium injection (PFR) 750mg IV/IM Ref
- cefuroxime oral susp (PFR) 125mg/5mL Ref
- cloxacillin injection (PFR) 500mg IV/IM HC4
- flucloxacillin capsule 250mg HC4
6.2.2 Other antibacterial drugs

chloramphenicol injection (PFR) 1G IV/IM HC3
chloramphenicol capsule 250 mg HC4
ciprofloxacin tablet 250mg HC3
ciprofloxacin tablet 500mg HC3
cotrimoxazole tablet 120mg HC2
cotrimoxazole tablet 480mg HC2
cotrimoxazole syrup 240mg/5mL HC2
doxycycline tablet 100mg HC2
erthyromycin oral susp (PFR) 125mg/5mL HC4
erthyromycin tablet 250mg HC2
gentamicin injection 40mg/mL IV/IM HC4
metronidazole infusion 5mg/mL H
metronidazole tablet 200mg HC2
nalidixic acid tablet or capsule 500mg H
nitrofurantoin tablet 100mg HC2

6.2.3 Antileprosy drugs

1 may be available at designated health centres

clofazimine capsule 100mg R
dapsone tablet 100mg R
rifampicin2 tablet or capsule 150mg R
thalidomide tablet 50mg R

6.2.4 Antituberculosis drugs

etambutol tablet 400mg HC4
ethambutol + isoniazid tablet 400mg+150mg HC4
isoniazid tablet 100mg HC4
pyrazinamide tablet 500mg HC4
rifampicin + isoniazid2 tab or cap 150mg+100mg HC4
rifampicin + isoniazid2 tab or cap 300mg+150mg HC4
rifampicin + isoniazid2 syrup 100mg+50mg/5mL HC4
streptomycin injection (PFR) 1G deep IM HC4

2 rifampicin products are reserved for TB/Leprosy Programme use only
6.3 Antifungal drugs

amphotericin B inj (PFR) 50mg for IV inf  Ref
clotrimazole pessary 500mg  HC4
fluconazole tablet or capsule 50mg  Ref
fluconazole tablet or capsule 100mg  Ref
fluconazole tablet or capsule 200mg  Ref
flucytosine injection 10mg/mL for IV inf Ref
griseofulvin tablet 125mg  HC3
griseofulvin tablet 500mg  HC3
ketoconazole oral susp 100mg/5mL  HC3
ketoconazole tablet 200mg  HC3
miconazole pessary 100mg  HC4
nystatin pessary 100,000 IU  HC3
nystatin oral susp 100,000 IU/mL  HC2
nystatin tablet 500,000 IU  HC3

6.4 Antiprotozoal drugs

6.4.1 Antiamoebic drugs

metronidazole tablet 200mg HC2
tinidazole tablet 500mg HC4

6.4.2 Antileishmaniasis drugs

pentamidine isethionate inj (PFR) 200mg deep IM  HC4
sodium stibogluconate inj 100mg/mL antimony IV/IM R

6.4.3 Antimalarial drugs

amodiaquine tablet 200mg  HC3
artemether injection 100mg IM  HC4
artemether tablet 50mg  HC4
chloroquine inj 40mg base/mL IM/SC  HC2
chloroquine tablet 150mg base  HC1
chloroquine syrup 75mg base/5mL  HC1
primaquine tablet 7.5mg  HC4
proguanil tablet 100mg  HC4
quinine inj 300mg/mL IV/deep IM HC3
quinine tablet 300mg  HC4
quinine mixture 100mg/5mL  HC4
sodium artesunate tablet 50mg  HC4
sulfadoxine + pyrimethamine tablet 500mg + 25mg (SP) HC1

6.4.4 Antitrypanosomal drugs (African trypanosomiasis)
6.4.5 Antitrichomoniasis drugs

- tinidazole tablet 500mg HC4

6.4.6 Drugs used in toxoplasmosis

- clindamycin capsule 150mg HC4
- pyrimethamine tablet 25mg HC4

6.5 Antiviral drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>aciclovir</td>
<td>tablet</td>
<td>200mg</td>
<td>HC4</td>
</tr>
<tr>
<td>aciclovir</td>
<td>tablet</td>
<td>400mg</td>
<td>HC4</td>
</tr>
<tr>
<td>ganciclovir sodium</td>
<td>injection (PFR)</td>
<td>500mg IV inf</td>
<td>R</td>
</tr>
</tbody>
</table>

7. ANTIMIGRAINE DRUGS

7.1 Treatment of Acute Attacks

- acetylsalicylic acid tablet 300mg HC1
- ergotamine tablet 1mg HC4
- paracetamol tablet 500mg HC1

7.2 Prophylaxis

- propranolol tablet 10mg HC4
- propranolol tablet 20mg HC4

8. ANTINEOPLASTIC & IMMUNOSUPPRESSIVE DRUGS

8.1 Immunosuppressive drugs

- azathioprine tablet 50mg R

8.2 Cytotoxic drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Strength</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>asparaginase (colaspase)</td>
<td>injection (PFR)</td>
<td>100mg</td>
<td>Ref</td>
</tr>
<tr>
<td>calcium folinate (folinic acid)</td>
<td>tablet</td>
<td>15mg</td>
<td>Ref</td>
</tr>
<tr>
<td>calcium folinate (folinic acid)</td>
<td>injection</td>
<td>3mg/mL IV/IM/IVin</td>
<td>Ref</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>injection (PFR)</td>
<td>500mg IV</td>
<td>Ref</td>
</tr>
</tbody>
</table>
8.3 Hormones and antihormones

cyclophosphamide tablet 50mg Ref
cytarabine inj (PFR) 100mg SC/IV/IT Ref
dacarbazine injection (PFR) 100mg IV Ref
dactinomycin injection (PFR) 500µg IV Ref
daunorubicin injection (PFR) 50mg IV/inf Ref
doxorubicin (adriamycin) injection (PFR) 50mg IV/inf Ref
fluorouracil injection 500mg/10mL IV R
hydroxyurea capsule 500mg R
mercaptopurine tablet 50mg R
methotrexate tablet 2.5mg R
methotrexate injection 50mg/mL IV/IM/IT Ref
mustine injection (PFR) 10mg IV/inf R
procarbazine capsule 50mg R
stilboestrol tablet 5mg R
thioguanine tablet 40mg R
vincristine injection (PFR) 1mg IV R
vincristine injection (PFR) 5mg IV R

dexamethasone tablet 4mg HC4
dexamethasone inj 4mg/mL IM/slow IV/IVinf HC4
prednisolone tablet 5mg HC4
tamoxifen tablet 10mg HC4

9. ANTI-PARKINSONISM DRUGS

benzhexol tablet 2mg HC4
benztropine injection 1mg/mL IV/IM HC4
levodopa + carbidopa tablet 100mg + 10mg Ref
levodopa + carbidopa tablet 250mg + 25mg Ref

10. DRUGS AFFECTING THE BLOOD

10.1 Antianaemia drugs

ferrous salt tablet 60mg elemental iron HC1
ferrous sulphate oral solution paediatric BP HC2
ferrous sulphate + folic acid tab 60mg elem.iron + 400µg HC1
folic acid tablet 1mg HC2
folic acid tablet 5mg HC2
hydroxocobalamin injection 1mg/mL IM HC4

10.2 Anticoagulants and antagonists
10.3 Fibrinolytic Agents

streptokinase injection 250,000 IU slow IV R

11. BLOOD PRODUCTS & PLASMA SUBSTITUTES

11.1 Plasma expanders

dextran 70 infusion IV 6% HC4
polygeline solution infusion IV 3.5% HC4

11.2 Plasma extracts

factor IX complex concentrate injection freeze-dried IV R
factor VIII concentrate injection freeze-dried IV R
albumin, human injection freeze-dried 25% IV R

12. CARDIOVASCULAR DRUGS

12.1 Antianginal drugs

atenolol tablet 100mg H
glyceryl trinitrate tablet sublingual 500µg H
glyceryl trinitrate patch 200µg H
isosorbide dinitrate tablet sublingual 5mg H
nifedipine tablet 10mg H

12.2 Antidysrhythmic drugs

atenolol tablet 100mg H
lignocaine inj 20mg/mL (2%) slow IV/IVinf Ref
procainamide tablet 250mg Ref
propranolol injection 1mg/mL slow IV Ref
propranolol tablet 40mg H
quinidine tablet 200mg Ref
verapamil tablet 40mg Ref

12.3 Antihypertensive drugs

atenolol tablet 100mg H
12.4 Drugs used in heart failure

12.4.1 Cardiac glycosides

digoxin tab paed 62.5µg (0.0625mg) HC4
digoxin tablet 250µg (0.25mg) HC4
digoxin injection 250µg/mL IV HC4

12.4.2 Drugs used in vascular shock

dopamine injection 40mg/mL IVinf H
epinephrine (adrenaline) injection 1mg/mL IC/IVinf HC4
hydrocortisone sod. succinate injection (PFR) 100mg IV/IM HC3

13. DERMATOLOGICAL DRUGS

13.1 Topical antifungals

benzoic acid + salicylic acid ointment 6% + 3% HC2
clotrimazole cream 1% HC3
miconazole cream 2% H
nystatin cream or oint 100,000 IU/g HC3
sulphur + salicylic acid cream or oint 2% + 2% Hosp

13.2 Topical antiinfectives

acetic acid solution 10% H
chlorhexidine cream 5% HC4
framycetin impregnated gauze 1% HC3
iodine tincture 2% HC1
methylrosanilinium chloride aqueous paint 1% HC1 (gentian violet)
neomycin + bacitracin ointment 5mg + 500IU/g H
potassium permanganate solution aq 1:10,000 (0.01%) HC4
silver sulphadiazine cream 1% HC3

13.3 Topical antiinflammatories and antipruritics
betamethasone cream or ointment 0.1% HC4
calamine lotion 15% H
hydrocortisone cream or ointment 1% HC3

13.4 Keratoplastics and keratolytics

benzoyl peroxide lotion or cream 5% HC4
coil tar ointment 1% H
dithranol ointment 0.1% H
podophyllum resin paint 15% HC4
salicylic acid ointment 2% HC2
salicylic acid ointment 5% HC2

13.5 Scabicide

benzyl benzoate lotion 25% HC2

13.6 Pediculicide

malathion lotion aqueous 0.5% HC2

13.7 Other topical preparations

silver nitrate stick 40% HC3

14. DIAGNOSTIC AGENTS

14.1 Ophthalmic diagnostic agents

1 for use only where ophthalmological expertise is available

fluorescein eye drops 1% HC4
physostigmine eye drops 0.25% HC4
rose bengal eye drops 1% HC4

14.2 Radiocontrast media

barium sulphate powder in water 75% w/v or more H
diatrizoate injection 60% H
diatrizoate injection 76% H
iodised oil fluid injection 38% H
ioglycamate injection 17% H
ioglycamate injection 35% H
iohexol injection 18% H
iohexol injection 24% H
iohexol injection 30% H
15. DISINFECTANTS and ANTISEPTICS

15.1 Antiseptics

cetrimide + chlorhexidine solution 0.5% + 0.05% HC2
chlorhexidine gluconate solution 20% HC2
hydrogen peroxide solution 6% HC2
povidone iodine solution 10% HC3

calcium or sodium hypochlorite solution 5% HC1

15.2 Disinfectants

calcium or sodium hypochlorite solution 5% HC1

16. DIURETICS

bendrofluazide tablet 5mg HC3
furosemide inj 10mg/mL IM/slow IV/IVinf HC4
furosemide tablet 40mg HC4
mannotol injectable sol. 20% IVinf H
spironolactone tablet 50mg HC4

17. GASTROINTESTINAL DRUGS

17.1 Antacids and other antiulcer drugs

bismuth chelate tablet 120mg Ref
cimetidine tablet 400mg HC4
magnesium trisilicate co. Tablet 370mg HC1
omeprazole tablet 20mg H
ranitidine tablet 150mg H

cyclizine tablet 50mg Ref

cyclizine inj 50mg/mL IM/slow IV Ref
domperidone tablet 10mg H
domperidone suspension 5mg/5mL H
domperidone suppository 30mg H
prochlorperazine tablet 5mg HC3
17.3 Antihaemorrhoidals

bismuth subgallate compound suppository HC3

17.4 Antispasmodics

hyoscine butylbromide injection 20mg/mL Ref
propantheline tablet 15mg H

17.5 Laxatives

bisacodyl tablet 5mg HC4
bisacodyl suppository paediatric 5mg HC4
senna tablet 7.5mg HC2

17.6 Drugs used in diarrhoea

17.6.1 For oral rehydration

oral rehydration salts powder for 1L (WHO citrate formula) HC1

17.6.2 Antidiarrhoeals¹

¹ for symptomatic treatment of adults only

codeine phosphate tablet 30mg HC4
loperamide tablet or capsule 2mg H

18. HORMONES, OTHER ENDOCRINE DRUGS & CONTRACEPTIVES

18.1 Adrenal hormones & synthetic substitutes

ACTH (corticotrophin) injection 20IU/mL IM Ref
betamethasone tablet 0.5mg Ref
cortisone tablet 12.5mg Ref
cortisone tablet 25mg Ref
dexamethasone tablet 4mg H
dexamethasone inj 4mg/mL IM/slow IV/ivinf H
hydrocortisone sod succinate inj 100mg IM/slow IV/ivinf HC3
prednisolone tablet 5mg HC4
18.2 Androgens

- methyltestosterone tablet 5mg Ref
- testosterone enanthate inj oily 250mg/mL slow IM Ref

18.3 Hormonal contraceptives

- ethinylestradiol + levonorgestrel tablet 30µg +150µg HC2
- ethinylestradiol + levonorgestrel tablet 30µg +300µg HC2
- ethinylestradiol + levonorgestrel tablet 50µg +250µg HC2
- ethinylestradiol + norethisterone tablet 50µg + 1mg HC2
- medroxyprogesterone acetate depot inj 150mg/mL deep IM HC3
- levonorgestrel implant capsules 38mg/cap H
- norgestrel tablet 75µg HC2

18.4 Oestrogens

- stilboestrol tablet 1mg Ref
- stilboestrol tablet 5mg Ref

18.5 Insulins and other antidiabetic agents

- glibenclamide tablet 5 mg HC4
- insulin soluble inj 40 IU/mL or 100 IU/mL SC1 HC4
- insulin zinc suspension (lente) inj 40 IU/mL or 100 IU/mL SC1 HC4
- isophane insulin injection 100 IU/mL SC HC4
- metformin tablet 500mg Ref
- metformin tablet 850mg Ref
- tolbutamide tablet 500 mg HC4

1 The 40IU/mL strength is to be phased out

18.6 Ovulation inducers

- bromocriptine tablet 2.5mg Ref
- clomifene tablet 50mg Ref

18.7 Progestogens

- norethisterone tablet 5 mg H

18.8 Thyroid hormones and antithyroid drugs

- carbimazole tablet 5mg H
- levothyroxine tablet 100µg HC4
- iodine + potassium iodide oral solution 5% + 10% (Lugol’s iodine) HC4
19. IMMUNOLOGICALS

2 See individual product literature for more information

19.1 Immunological diagnostic agents

tuberculin PPD injection 100 IU/mL HC3

19.2 Sera and immunoglobulins

- anti-D immunoglobulin human injection 250µg/mL IM Ref
- antirabies immunoglobulin, human injection 200 IU/mL HC4
- antirabies vaccine, human diploid IM/local infiltration
- antiscorpion serum injection Ref
- antitetanus immunoglobulin, human injection 500 IU IM Ref
- antivenom sera polyvalent (East & Central Africa) injection IV HC4
- diphtheria antitoxin injection 10,000 IU IM Ref
- normal immunoglobulin, human injection 16% IM Ref

19.3 Vaccines

19.3.1 Vaccines for routine immunisation

- BCG vaccine dried injection ID 20 dose vial HC2
- diphtheria-pertussis-tetanus (DPT) injection IM/deep SC (20 dose vial) HC2
- measles vaccine injection IM/deep SC (10 dose vial) HC2
- poliomyelitis vaccine (live attenuated) oral solution 20 dose HC2
- tetanus toxoid vaccine (20 dose vial) injection IM/deep SC HC2

19.3.2 Vaccines for specific groups of individuals

- hepatitis B vaccine inj IM/deep SC single dose HC2
- meningococcal vaccine A+C inj IM/deep SC single dose HC2
- plague vaccine inj IM/deep SC single dose HC2
- rabies vaccine human diploid inj IM/deep SC single dose HC2
- rubella vaccine inj IM/deep SC single dose H
- typhoid vaccine inj IM/deep SC single dose HC2
- yellow fever vaccine inj SC single dose HC2

20. MUSCLE RELAXANTS & CHOLINESTERASE INHIBITORS

- alcuronium chloride injection 5mg/mL IV Ref
- atracurium besylate injection 10mg/mL Ref
- edrophonium injection 10mg/mL IV H
- neostigmine tablet 15mg HC4
- neostigmine injection 500µg/mL IM/SC H
21. OPTHALMOLOGICAL PREPARATIONS

21.1 Antiinfective agents

- aciclovir eye ointment 3% Ref
- chloramphenicol eye ointment 1% HC2
- chloramphenicol eye drops 0.5% HC2
- gentamicin eye/ear drops 0.3% HC4
- idoxuridine eye drops 0.1% Ref
- idoxuridine eye ointment 0.5% Ref
- tetracycline eye ointment 1% HC1

21.1.1 Antiinfective + antiinflammatory agents

1 for use only where qualified ophthalmological staff is available

- neomycin + betamethasone eye drops 0.5% + 0.1% HC4
- hydrocortisone + eye drops 1.5% + HC4
- oxytetracycline + polymyxin B 0.5% + 0.119%

21.2 Antiinflammatory agents

1 for use only where qualified ophthalmological staff is available

- betamethasone eye drops 0.1% HC4
- hydrocortisone eye drops 0.5% HC4
- hydrocortisone eye ointment 1% HC4

21.3 Local anaesthetics

1 for use only where qualified ophthalmological staff is available

- tetracaine (amethocaine) eye drops 0.5% H
- tetracaine (amethocaine) eye drops 1% H

21.4 Miotics and antiglaucoma drugs

1 for use only where qualified ophthalmological staff is available

- pancuronium bromide injection 2mg/mL IV Ref
- suxamethonium injection 50mg/mL IV/IVinf HC4
- tubocurarine injection 10mg/mL IV H
acetazolamide tablet 250mg HC4
pilocarpine eye drops 2% HC4
pilocarpine eye drops 4% HC4
timolol eye drops 0.25% Ref
timolol eye drops 0.5% Ref

21.5 Mydriatics¹

¹ For use only where ophthalmological expertise available

atropine eye drops 1% H
cyclopentolate eye drops 2% Ref
phenylephrine eye drops 10% HC

21.6 Astringents¹

¹ For use only where ophthalmological expertise available

zinc sulphate eye drops 0.25% HC4

22. OXYTOCICS & ANTI-OXYTOCICS

22.1 Oxytocics

ergometrine tablet 200µg HC4
ergometrine + oxytocin injection 500µg + 5 IU/mL IM HC2
methylergometrine inj 200µg/mL IM/slow IV HC2
oxytocin inj 10 IU/mL slow IV/inf H

22.2 Antioxytocics

salbutamol tablet 4mg HC3
salbutamol injection 1mg/mL IV inf HC4

23. PERITONEAL & HAEMODIALYSIS SOLUTIONS

electrolyte solutions for dialysis² Ref

² See product literature for details of presentation

24. PSYCHOTHERAPEUTIC DRUGS

amitriptyline tablet 25mg HC4
carbamazepine tablet 200mg HC4
chlordiazepoxide tablet 10mg HC4
25. DRUGS ACTING ON THE RESPIRATORY TRACT

25.1 Antiasthmatic drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>aminophylline</td>
<td>tablet 100 mg</td>
<td>HC3</td>
</tr>
<tr>
<td>aminophylline</td>
<td>inj 25mg/mL slow IV/IVinf</td>
<td>HC4</td>
</tr>
<tr>
<td>beclometasone</td>
<td>inhaler 50µg/metered dose</td>
<td>HC4</td>
</tr>
<tr>
<td>epinephrine (adrenaline)</td>
<td>injection 1mg/mL SC</td>
<td>HC2</td>
</tr>
<tr>
<td>salbutamol</td>
<td>nebuliser solution 2.5mg/mL</td>
<td>H</td>
</tr>
<tr>
<td>salbutamol</td>
<td>nebuliser solution 5mg/mL</td>
<td>H</td>
</tr>
<tr>
<td>salbutamol</td>
<td>inhaler 100µg/metered dose</td>
<td>HC4</td>
</tr>
<tr>
<td>salbutamol</td>
<td>tablet 4mg</td>
<td>HC3</td>
</tr>
<tr>
<td>sodium cromoglycate</td>
<td>inhaler 5mg/metered dose for adults</td>
<td>HC4</td>
</tr>
</tbody>
</table>

25.2 Antitussive drug

codeine phosphate tablet 30mg (for adults) HC4

25.3 Cough soothing preparation

simple linctus syrup (BNF formula) HC2

26. SOLUTIONS CORRECTING WATER, ELECTROLYTE, & ACID-BASE DISTURBANCES
26.1 For oral rehydration

oral rehydration salts powder for 1 L WHO citrate formula) HC1

26.2 Parenterals

calcium gluconate injection 100mg/mL (10%) HC1
darrow’s solution infusion ½ strength in 2.5% glucose HC2

26.3 Miscellaneous

water for injection injection 2mL IV/IM HC2
water for injection injection 5mL IV/IM HC2
water for injection injection 10mL IV/IM HC2

27. VITAMINS & MINERALS

ascorbic acid (vitamin C) tablet 100mg HC3
calcium lactate tablet 300mg HC3

28. EAR, NOSE & OROPHARYNGEAL PREPARATIONS

28.1 Ear preparations

betamethasone ear/eye drops 0.1% H
28.2 Nasal preparations

- beclometasone nasal spray 50µg/metered dose H
- ephedrine nasal drops 1% (for adults) H
- lignocaine + adrenaline nasal drops 2% +1:100,000 Ref
- xylometazoline nasal drops 0.05% HC4
- xylometazoline nasal drops 0.1% HC4

28.3 Oropharyngeal preparations

- lidocaine (lignocaine) lozenges 4% HC4
- lidocaine (lignocaine) spray 5% HC4
- miconazole oral gel 2% HC4
- povidone-iodine mouthwash/gargle 1% HC3
- triamcinolone acetonide oral paste 0.1% H

29. DRUGS FOR NEUROSURGICAL USE

29.1 For cerebral metabolism/perfusion

- piracetam tablet 800mg R
- piracetam injection 125mg/mL IV/IM R